Canada markets closed

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.41-0.25 (-2.59%)
At close: 4:00PM EDT
9.41 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.66
Open9.53
Bid9.40 x 1400
Ask9.80 x 1000
Day's Range9.28 - 9.90
52 Week Range8.28 - 25.18
Volume12,925
Avg. Volume32,846
Market Cap69.223M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-4.49
Earnings DateNov. 09, 2021 - Nov. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.75
  • GlobeNewswire

    Delcath Systems to Present at Upcoming Virtual Investor Conferences

    NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences: H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021 Presentation Date and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)Webcast: https://journey.ct.events/view/ee8971f7-2bcf-428c-91e5-3ff7d70376abManage

  • GlobeNewswire

    Delcath Systems Announces Second Quarter 2021 Results

    NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021. Recent Business Highlights During and since the second quarter the company: Had positive efficacy results presented from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/he

  • GlobeNewswire

    Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

    NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company's Current Report on Form